Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Frontiers in Endocrinology|November 30, 2017
Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?Roberta Malaguarnera, Veronica Vella, Maria Luisa Nicolosi, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|August 9, 2019
Insulin/IGF signaling and discoidin domain receptors: An emerging functional connectionVeronica Vella, Roberta Malaguarnera, Maria Luisa Nicolosi, et al.
Frontiers in Endocrinology|March 10, 2017
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF AxisVeronica Vella, Maria Luisa Nicolosi, Stefania Giuliano, et al.
Cells|September 5, 2019
Insulin Receptor Isoform A Modulates Metabolic Reprogramming of Breast Cancer Cells in Response to IGF2 and Insulin StimulationVeronica Vella, Maria Luisa Nicolosi, Marika Giuliano, et al.
Cell Adhesion & Migration|March 1, 2018
A novel functional crosstalk between DDR1 and the IGF axis and its relevance for breast cancerAntonino Belfiore, Roberta Malaguarnera, Maria Luisa Nicolosi, et al.
The Journal of Clinical Endocrinology and Metabolism|July 8, 2015
Thyrospheres From Normal or Malignant Thyroid Tissue Have Different Biological, Functional, and Genetic FeaturesFiorenza Gianì, Veronica Vella, Maria Luisa Nicolosi, et al.
Thyroid : Official Journal of the American Thyroid Association|May 3, 2014
The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcomeMarco Russo, Pasqualino Malandrino, Maria Luisa Nicolosi, et al.
International Journal of Cancer|June 8, 2011
Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cellsRosa Linda Messina, Mariangela Sanfilippo, Veronica Vella, et al.
The Journal of Clinical Endocrinology and Metabolism|April 6, 2013
Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathwayFrancesco Frasca, Veronica Vella, Maria Luisa Nicolosi, et al.
Oncotarget|June 8, 2017
Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cellsVeronica Vella, Roberta Malaguarnera, Maria Luisa Nicolosi, et al.
Pageof 2